In vivo imaging of pancreatic tumours and liver metastases using 7 Tesla MRI in a murine orthotopic pancreatic cancer model and a liver metastases model by Partecke, Ivo L et al.
RESEARCH ARTICLE Open Access
In vivo imaging of pancreatic tumours and liver
metastases using 7 Tesla MRI in a murine
orthotopic pancreatic cancer model and a liver
metastases model
Ivo L Partecke
1, André Kaeding
1, Matthias Sendler
2, Nele Albers
1, Jens-P Kühn
3, Sven Speerforck
1, Sebastian Roese
1
, Florian Seubert
1, Stephan Diedrich
1, Sandra Kuehn
1, Ulrich F Weiss
2, Julia Mayerle
2, Markus M Lerch
2,
Stefan Hadlich
3, Norbert Hosten
3, Claus-D Heidecke
1, Ralf Puls
3, Wolfram von Bernstorff
1*
Abstract
Background: Pancreatic cancer is the fourth leading cause of tumour death in the western world. However,
appropriate tumour models are scarce. Here we present a syngeneic murine pancreatic cancer model using 7 Tesla
MRI and evaluate its clinical relevance and applicability.
Methods: 6606PDA murine pancreatic cancer cells were orthotopically injected into the pancreatic head. Liver
metastases were induced through splenic injection. Animals were analyzed by MRI three and five weeks following
injection. Tumours were detected using T2-weighted high resolution sequences. Tumour volumes were
determined by callipers and MRI. Liver metastases were analyzed using gadolinium-EOB-DTPA and T1-weighted
3D-Flash sequences. Tumour blood flow was measured using low molecular gadobutrol and high molecular
gadolinium-DTPA.
Results: MRI handling and applicability was similar to human systems, resolution as low as 0.1 mm. After 5 weeks
tumour volumes differed significantly (p < 0.01) when comparing calliper measurments (n = 5, mean 1065 mm
3
+/-243 mm
3) with MRI (mean 918 mm
3+/-193 mm
3) with MRI being more precise. Histology (n = 5) confirmed MRI
tumour measurements (mean size MRI 38.5 mm
2+/-22.8 mm
2 versus 32.6 mm
2+/-22.6 mm
2 (histology), p < 0,0004)
with differences due to fixation and processing of specimens. After splenic injection all mice developed liver
metastases with a mean of 8 metastases and a mean volume of 173.8 mm
3+/-56.7 mm
3 after 5 weeks.
Lymphnodes were also easily identified. Tumour accumulation of gadobutrol was significantly (p < 0.05) higher
than gadolinium-DTPA. All imaging experiments could be done repeatedly to comply with the 3R-principle thus
reducing the number of experimental animals.
Conclusions: This model permits monitoring of tumour growth and metastasis formation in longitudinal non-
invasive high-resolution MR studies including using contrast agents comparable to human pancreatic cancer. This
multidisciplinary environment enables radiologists, surgeons and physicians to further improve translational
research and therapies of pancreatic cancer.
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Pancreatic cancer is the third most common cause of
gastrointestinal malignancies and the fourth leading
cause of cancer death in the northern hemisphere. Pan-
creatic cancer accounts for approximately 33,000 cancer
deaths in the United States and almost 13,000 in Ger-
many [1-3]. Despite significant improvements in surgical
and non-surgical treatment modalities including new
possible therapeutic targets [4,5] the almost unchanged
5-year survival rate of 5% remains poor. This is also
mirrored by the general lack of effective medical treat-
ment options [6]. Therefore, reproducible preclinical
models are required to study the underlying causes of
tumour development, growth and dissemination of pan-
creatic cancer. Also, these models are crucial for the
development of new and effective treatment modalities
as well as the evaluation of diagnostic imaging techni-
ques for monitoring tumour growth and metastasis
formation.
Currently, several mouse models of pancreatic cancer
have been established [7]. These include subcutaneously
[8,9] and/or orthotopically [10,11] implanted xenografts
of human tumour cells into SCID or nude mice i.e.
using mice with defects of their immune system. Even
lung metastases may be generated with these models
[8,9]. Other models include the orthotopic injection or
transplantation of established syngeneic pancreatic
mouse cancer cell lines like Panc02 [12,13] or 6606PDA
[14] into the appropriate immuno-competent mouse
strain. Further research has succeeded in the develop-
ment of new syngeneic orthotopic models as recently
published by Tseng et al. [15].
The aim of this study was the evaluation of clinically
relevant murine pancreatic cancer models for longitudi-
nal diagnostic and therapeutic studies. An orthotopic
pancreatic cancer model as well as a liver metastases
model using the cell line 6606PDA [14] were studied
using a 7 Tesla magnetic resonance imager. The moni-
toring of tumour growth and the formation of metas-
tases was examined focussing on the possibility of
reducing the number of animals needed for long term
follow-up according to the 3R-principles (reduction,
replacement and refinement of research animals)
described by Russel and Burch 1959 [16]. The complete
system mimics the human clinical situation including
the cooperation of medical, surgical and radiological
specialists.
Methods
Laboratory Animals
Six to eight weeks old male C57/BL6 mice with a body
weight of 20 to 23 g were obtained from Charles River
Laboratories (Bad Sulzfeld, Germany) and allowed to
adapt to the new surrounding for about seven to
fourteen days. They were maintained in a specific patho-
gen-free environment receiving sterilized food (ssniV R-
Z, ssniV Spezialdiäten GmbH, Soest, Germany) and tap
water ad libitum. Stress levels were kept to a minimum
before starting experiments. Animal rooms had a twelve
to twelve hour light-dark/day-night cycle and were
maintained at constant temperature and humidity.
Before starting experiments all animal studies had been
approved by the ethics committee for animal care of
Mecklenburg-Vorpommern, Germany.
Cell Line and Culture
The murine pancreatic adenocarcinoma cell line
6606PDA was a kind gift from Prof. David Tuveson,
Cambridge, UK [14]. 6606PDA cells have been isolated
f r o map a n c r e a t i ca d e n o c a r c i n o m ao fat r a n s g e n i cC 5 7 /
BL6 mouse carrying a Kras
D12G allele. Cells were main-
tained in RPMI-1640 medium supplemented with 10%
fetal calf serum, 100 U/ml of penicillin and 100 μg/ml
of streptomycin (referred to as “complete medium”).
Tissue culture reagents were obtained from Gibco (Invi-
trogen, Carlsbad, California, USA). Cell cultures were
kept in a humidified incubator at 37°C with 5% CO2.
Cell cultures were kept pathogen-free and were regularly
tested for Mycoplasma species. They were consistently
negative for Mycoplasma contamination.
Orthotopic Injection Technique
Subconfluent cultures of 6606PDA cells were harvested
using a 0.05% Trypsin-solution, washed twice in PBS,
and re-suspended as single-cell suspensions in serum-
free RPMI-1640. Cell viability was tested using trypan
blue exclusion. Viability was always greater than 95%.
General anaesthesia in mice was induced using a com-
bination of ketamine hydrochloride (Ketanest S
® Pfizer
Pharma, Berlin, Germany) and xylometazoline hydro-
chloride (Rompun
® Bayer HealthCare, Berlin, Germany)
at concentrations of 87 mg/kg and 13 mg/kg injected
intraperitoneally. The abdominal cavity was opened by a
1.5 cm wide transverse laparotomy pointing slightly to
the right. The head of the pancreas was identified and
lifted up by a cotton wool tip. 2.5 × 10
5 tumour cells in
a total volume of 20 μl consisting of equal volumes of
PBS and matrigel (Matrigel™ Basement Membrane
M a t r i x ,B DB i o s c i e n c e ,S a nJ o s é ,C A ,U S A )w e r es l o w l y
injected into the head of the pancreas using a 27-gauge
needle. Matrigel is a substance with a more watery con-
sistency at 4°C but turns into a gel-like substance when
reaching temperatures above 22°C. It was used to pre-
vent local spillage and thereby the early development of
local peritoneal tumour growth. To further prevent leak-
age a cotton wool tip was pressed onto the injection site
for 30 seconds. To ensure the same injection technique
for all experiments the injection was always carried out
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replaced into the abdominal cavity. The abdominal cav-
ity was closed by a running single layer 4/0 polyester
suture (Catgut, Markneukirchen, Germany). To decrease
post surgical pain and the effects of surgery we subcuta-
neously injected buprenorphine hydrochloride at a dose
of 0,1 mg/kg. So far, we have not had any fatalities
related to surgery.
Induction of liver metastases by splenic injection
General anaesthesia in mice was induced as above. The
abdominal cavity was opened by a 0.5 cm left sided
transverse laparotomy. The spleen was identified and
lifted up by a cotton wool tip. 5 × 10
5 6606PDA cells in
a total volume of 50 μl of PBS were injected subcapsu-
larly into the spleen using a 27 gauge needle. To prevent
leakage a cotton wool tip was pressed onto the injection
site for 30 seconds. The closure of the abdominal cavity
and post surgical pain therapy were carried out as
above. Following this splenic injection technique we
have not had any surgery related fatalities either.
7 Tesla MRI
For all MRI studies anaesthesia had to be carried out
using isoflurane (1% - 1.5%). The depth of anaesthesia
was monitored by the breathing rate. MRI sequences
were triggered by the breathing rate. An anaesthesia
adjusted breathing rate of 40 per minute was found to
be optimal. To reduce the influence of bowel motility in
all MRI examinations mice were always kept nil per os
(NPO) for at least 4 hours before starting MRI scans.
For MRI scans all mice were kept in a supine position
(Figure 1). For all MRI studies mice were scanned after
3 and after 5 weeks of tumour injection. However, other
intervals and more frequent scans can be done without
any obvious harm to the mice.
Tumour bearing mice were scanned in a high field 7.0
Tesla MRI scanner for small animals (Bruker, ClinScan,
7.0 Tesla, 290 mTesla/m gradient strength (Bruker,
Ettlingen, Germany)). MRI analyses were performed in a
whole mouse body coil (Figure 2, Bruker, Ettlingen, Ger-
many) using a T2-TSE (turbo spin echo) sequence. The
whole body coil is a volume coil that allows the imaging
of the whole mouse without inducing any inhomogene-
ities of the signal. For the assessment of tumour sizes
we used high resolution T2-weighted images of the
frontal as well as the horizontal plane (frontal plane: TR
(repetition time): ca. 1200 ms; TE (echo time): 41.0 ms;
FA (flip angle): 180°; FoV (field of view): 42 mm × 42
mm; matrix: 240 × 320; 24 slices of 0,7 mm per slice,
acquisition time: ca. 15 min; horizontal plane: TR: ca.
1250 ms; TE: 41.0 ms; FA: 180°; FoV: 40 mm × 40 mm;
matrix: 240 × 320; 24 slices of 0.7 mm per slice, acquisi-
tion time: ca. 10 min). Generated images were analyzed
employing MIPAV (medical imaging processing and
visualisation, National Institutes of Health, Bethesda,
Maryland, USA). All image slices of the tumours were
marked with so called regions of interest (ROI) which
facilitated the software calculation of the tumour
volume. This was finally done with a complex algorythm
using all image inherent information including thickness
of slices, resolution as well as size of ROIs.
The definition of ROI was carried out in a reproduci-
ble and standardized way by one investigator only (AK)
applied to all mice. However, difficult findings or images
were always discussed with a senior radiologist. The
investigator had been thoroughly trained by analyzing
numerous MR scans and optimized the MR analyses for
Figure 1 MRI equipment. Mouse prepared for MRI scan monitoring the vital parameters breathing rate, heart rate and temperature, position in
front of coil
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involved radiologists. Satellite tumours were considered
as part of the original tumour if there was true and con-
tinuous tumour between original tumour and satellite
tumour. Metastases and secondary tumours without
continuous tumour growth connecting to the original
tumour were excluded when measuring the primary
tumour. The tumour borders/edges could easily be iden-
tified even without contrast media due to their charac-
teristic shape and appearance. MR images were
compared with corresponding macroscopic tumour
growth on exploration and with corresponding micro-
scopic tumour growth using histological specimens.
To analyze the acquired MRI data we used CIT (Cen-
ter for Information Technology) and NIH (National
Institute of Health) developed algorithms in MIPAV-
software (Medical Image Processing and Visualization
[17]). To validate the used volumetric algorithms for
compatibility with our MRI-system we examined 1000
mm
3 water of defined volume (calibrated pipette) in a
standardized 1.5 ml Eppendorf tube as an MRI
phantom.
Imaging of liver metastases
For the generation of images of liver metastases 200 μl
of the contrast medium Gadolinium ethoxybenzyl
diethylenetriamine pentaacetic acid (Gd-EOB-DTPA;
gadoxetic acid disodium, Primovist
®, Bayer Schering
Pharma, Berlin, Germany) were injected intravenously
10 minutes before starting MRI scans. Primovist
® was
used at a concentration of 0.025 mmol/ml and was
injected via the tail vein. Also for these experiments
mice were kept in a supine position using the whole
mouse body coil. For the detection of liver metastases a
high resolution T1 flash3d-vibe („volumetric interpo-
lated breathhold examination”) weighted sequence was
used. Scans were carried out in the frontal as well as the
horizontal plane (frontal and horizontal plane: TR: ca.
10 ms; TE: 1.46 ms; FA: 12°; FoV: 50 mm × 50 mm;
matrix: 256 × 256; 48 slices of 0.3 mm each slice; acqui-
sition time: ca. 2:45 min.). This was followed by the gen-
eration of high resolution T2-weighted images in frontal
and horizontal planes as above. The volumes of liver
metastases as well as the volume of the liver itself were
calculated using MIPAV using the above described
algorithm.
Dynamic contrast enhanced MRI (DCE-MRI) for the
imaging of tumour blood flow
For imaging studies of the blood flow within the tumour
two different contrast media were used: the low molecu-
lar weight contrast medium gadobutrol (Gadovist
®,
Bayer Schering Pharma, Berlin, Germany) and the high
molecular weight contrast medium gadolinium-DTPA
(Gadomer
®, Bayer Schering Pharma, Berlin, Germany).
So far, neither of them has induced any adverse
reactions.
For imaging studies an intravenous catheter (26G BD
Vasculon™ Plus, BD, USA) was inserted into the tail
vein of the mouse. The catheter was connected with an
injection line and linked to the injection pump (Conti-
nuum MR System, Medrad, Indianola, PA, USA). Again,
for these experiments mice were kept in a supine posi-
tion using the whole mouse body coil. For the tumour
assessment two fast high resolution T2-weighted scans
were done: in the frontal as well as the horizontal plane
(frontal plane: TR: ca. 2030 ms; TE: 40.0 ms; FA: 180°;
FoV: 33 mm × 33 mm; matrix: 144 × 192; 15 slices at
1.5 mm each; acquisition time: ca. 2:53 min; horizontal
plane: TR: 2693 ms; TE: 41.0 ms; FA: 180°; FoV: 40 mm
× 40 mm; Matrix: 240 × 320; 5 slices at 2 mm each,
acquisition time: ca. 3:11 min).
Thereafter, the FoV was determined. It was always
essential to have the centre of the FoV within the largest
diameter of the tumour. This was followed by T1-
weighted pre-contrast scans (horizontal: TR: 500 ms;
TE: 14.6 ms; FA: 180°; FoV: 25 mm × 25 mm; matrix:
320 × 512 interpolated; 20 slices at 0.5 mm per slice;
acquisition time: 2:42 min). Several pre-contrast scans
were taken for an acquisition of a statistically stable
baseline After completing 9 pre-contrast scans the
dynamic contrast medium enhanced scans were per-
formed using the VIBE-recording technique (Volume
Interpolated Breathhold Examination, horizontal plane:
TR: ca. 3.98 ms; TE: 1.89 ms; FA: 12°; FoV: 50 mm × 50
mm; matrix: 192 × 256; 8 slices at 1.5 mm each slice,
acquisition time: 637 sec, total number of pictures: 130,
acquisition time: ca. 13:00 min). The contrast medium
was injected via the tail vein. The optimal concentration
and amount of the contrast medium was calculated
using the weight of the mouse. The standard concentra-
tion of the contrast medium was 0.1 mmol/kg body
weight, i.e. 0.0025 mmol/ml for a 25 g mouse. For a
Figure 2 Whole body mouse coil.
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of 200 μl within 3 seconds) an injection pump with
bolus function was used (Continuum MR System,
Medrad, Indianola, PA, USA).
To minimize the negative effects of changes in vital
parameters of the blood flow, microcirculation and the
distribution of the contrast medium the breathing rate,
the heart rate and the temperature were monitored
closely and kept within narrow limits (Figure 1: breath-
ing rate: 30-50/min.; heart rate: 200-400/min.; tempera-
ture: 36,5°C (+/- 0,5°C)).
The basis for measuring tumour blood flow was a
model in which the accumulation of contrast medium
w i t h i nt h et u m o u ro v e rt i m ew a su s e da st h em a r k e r .
The accumulation was analyzed through the change of
signal intensity within a defined ROI. This ROI was
placed around the whole tumour. Before injecting the
contrast agent/medium the base line of the signal inten-
sity was measured. For this altogether 10 analyses were
carried through. The mean of analyses 4 through 9 was
taken as the base line SI0. Then, the SI after injection of
t h ec o n t r a s tm e d i u mS I t was measured. To determine
an SI-index mirroring the accumulation of the contrast
agent within the tumour (i.e. the actual change of the
contrast agent over time) reflecting the tumour blood
flow the base line SI0 was subtracted from SIt divided by
the base line value: ΔSIt = (SIt -S I 0)/SI0
This SI-index ΔSIt was measured and calculated for
each animal. Finally, the mean SI-index of each group
was determined for comparisons between the groups.
This method using the above radiological and mathema-
tical means is feasible and reproducible for the exact
measurement of tumour blood flow. Furthermore, this
method could be used for analyzing different factors
that might influence tumour blood flow. The functional
distribution of the contrast medium within the tumour
tissue was analyzed using the two compartments model
of pharmacokinetics [18].
Calliper measurement and histological examination
Tumour-bearing animals were sacrificed 5 weeks after
tumour injection following the final MRI scan. Pancrea-
tic tumours and/or livers were resected. The volume of
tumours was estimated by electronic calliper measure-
ments. Tumour volume was calculated using the for-
mula for ellipsoid tumours V = L × W × H × (π/6).
L was the longest distance from right to left, W was the
largest dorsal/ventral diameter and H was the largest
rostral/caudal diameter [19]. Furthermore, histological
specimens and MR images were compared for tumour
volumes, tumour structure (e.g. necroses), and possible
infiltration of surrounding tissues. The number of
metastases was estimated by counting them in all
recorded image planes. The volume of metastases was
determined by MR measurement using the already
described methods.
All specimens were analyzed by histology, 5 sections
were cut per specimen for routine analysis. Specimens
were fixed in 10% buffered formalin, processed routi-
nely, and embedded in paraffin. Tumour rotation during
the embedding process was prevented by marking the
tumour/pancreatic specimen in situ e.g. by stitches or
markers. Then, after fixation, the specimens were trans-
ferred into the embedding chambers holding the speci-
mens in position until the paraffin was solid to prevent
further rotation. After cutting 4 μm serial sections they
were stained using haematoxylin and eosin. Sections
were evaluated for various pathologic parameters using
a light microscope (Leica, Wetzlar, Germany). Also, the
serially cut specimens (20 slides altogether per speci-
men) were compared with their corresponding MR
images. The appropriate matches were found when slide
and image showed the same landmarks.
Statistics
In vitro and in vivo results were statistically analyzed
using the program GraphPad InStat version 3.06
(GraphPad Software Inc., SanD i e g o ,C a l i f o r n i a ,U S A ) .
The unpaired or the paired t-test with Welch’s correc-
tion or the unpaired Mann-Whitney test (for non-Gaus-
sian distributions) or the Wilcoxon signed rank test
were taken to compare the means of values of the
experiments. A p-value below 0.05 was considered to be
statistically significant.
Results
Evaluation of tumour size
The validation of the used volumetric-algorithms for the
compatibility with our MR-system using Eppendorf
tubes showed a mean discrepancy to the expected
volume of 1.8% with a calculated mean of all coronal
and transverse planes of 982 mm
3 (SD +/- 27.2 mm
3).
The one sample t-test (p = 0.36) and the Wilcoxon
Signed Rank Test (p = 0.5) revealed no significant
(alpha = 0.05) difference to the hypothetical value of
1000 mm
3.
All mice orthotopically injected with tumour cells devel-
oped tumours within the head of the pancreas (i.e. 100%).
Survival analyses have shown a median survival of about
50 days. To study the size of tumours high resolution
T2-weighted images in the frontal as well as the horizontal
p l a n ew e r ea n a l y z e d .T h et u m o u rw i t h i nt h eh e a do ft h e
pancreas could be safely identified in all tumour bearing
animals. The tumours showed strong signal intensities.
With increasing tumour size a typical central zone of
tumour necrosis could be identified (Figure 3 and 4).
With the help of breathing rate triggered sequences
and the reduction of bowel motility by keeping mice
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ply. This was essential for the exact determination of
the tumour volume. Tumour growth could be closely
monitored over time (n = 5): 21 days following tumour
injection the mean tumour volume could be measured
at 540 mm
3 (range 253 to 835 mm
3, mean 540 +/- 220
mm
3). 35 days following tumour injection tumours had
increased in volume to 918 mm
3 (range 617 to 1118
mm
3, mean 918 mm
3 +/- 193 mm
3). In addition,
tumour size was assessed by using electronic callipers
using the formula LxWxHxΠ/6 (see above). Following
the last MRI scan after 35 days of tumour growth mice
were sacrificed and organs were harvested for further
analyses. Tumours measured by callipers were always
slightly larger compared to tumours measured by MRI
with a mean of 1065 mm
3 (range 708 - 1300 mm
3,+ / -
243 mm
3, p < 0.01, paired t-test compared to MRI
tumours, Figure 5). This difference was partly due to
surrounding tissues and particularly due to the method
of measuring the tumour size using the above formula
overestimating the total tumour volumes. This was con-
firmed in 2 consecutive experiments (n = 8 mice each
group) comparing MRI and calliper measurements with
expected differences in tumour sizes (395.5 mm
3
+/-181.0 mm
3 (MRI) versus 498.1 mm
3 +/-252.8 mm
3
(calliper), p = 0.069; and 316.5 mm
3 +/- 318 mm
3 (MRI)
versus 463.1 mm
3 +/-331.9 mm
3 (calliper) p < 0.007,
paired t-test).
Comparing MRI and histology (n = 5 mice, histological
slides = 20 for each specimen) there were only small
though significant but expected differences in tumour
sizes albeit standard deviations were the same. Tumour
sizes were compared by using similar sections of MR
images and specimen sections the size being measured
and compared after electronic scanning (Figure 4, mean
size MRI tumours 38.5 mm
2 +/-22.8 mm
2 versus 32.6
mm
2 +/- 22.6 mm
2 histological tumours, p < 0,0004,
paired t-test). This difference was due to tumour shrinking
A1 B1
B2 A2
Figure 3 Monitoring of tumour growth over time.T h e
orthotopically injected tumour into the head of the pancreas was
imaged after 3 und 5 weeks of tumour growth (NB: central necrosis
of the tumour): A: frontal plane; A1: 3 weeks; A2: 5 weeks B:
horizontal plane; B1: 3 weeks; B2: 5 weeks
np
n
d
Figure 4 Monitoring of tumour growth over time.C o m p a r i s o n
of tumour sizes using MRI and histology: Both pictures depict same
slice of tumour; right: tumour area equals 66.7 mm
2, left: 73.1 mm
2;
differences in tumour size (outlined) were due to fixation and
always present; yet, slides were well comparable: tumour and
surrounding tissues: tumour: within red frame, n: zone of necrosis,
np: normal pancreas, d: duodenum
tumourvolume after 3 and 5 weeks
21 days
35 days
calliper (35 days)
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Figure 5 Monitoring of tumour growth over time.T u m o u r
volumes after 3 weeks, 5 weeks (MRI) and after 5 weeks by calliper
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staining and coverslipping procedures of tumours and was
a systematic effect. Therefore, these differences were con-
stantly present and did not differ significantly between ani-
mals. Also, the standard deviation was almost exactly the
same, pointing out the systematic effect. Furthermore, the
very high spatial resolution of the 7 Tesla MRI enabled
the investigator to detect changes as small as 0.1 mm.
Therefore, tumour infiltration e.g. of the bowel could be
seen on MR images or MR changes were highly suggestive
of tumour infiltration. This was confirmed by histological
a n a l y s e s( F i g u r e3 ,4 ,6 ,7 ,a n d8 ) .I ns u m m a r y ,M R I
proved to be the most reliable and reproducible method
for the measurement of tumour volume and tumour size.
Furthermore, the initial injected volume of 20 μl( 2 0m m
3)
would have been easily detected by MRI. Yet, MRI imme-
diately after injection would have caused too much stress
to the mice. The earliest time point of MR imaging was 10
days following injection showing mean tumour volumes of
320 mm
3 (range 144 to 606 mm
3 +/- 187 mm
3,n=6 ) .
Matrigel has not shown any effects on tumour growth or
MR imaging. Previous in vitro experiments using matrigel
and without matrigel had shown almost similar growth
and migration of tumour cells. This was confirmed in in
vivo experiments (data not shown). Lymphnode metas-
tases were easily identified ranging from 0 to 8 (mean 4.5,
n = 5 mice) after 5 weeks in this tumour model (data not
shown). They presented as round hyper intense lesions
measuring up to 5.0 mm in diameter (Figure 8).
Imaging of liver metastases
Following splenic injection all animals (i.e. 100%, n = 5)
developed liver metastases. First, small tumours devel-
oped within the spleen before metastasizing via the
splenic and the portal vein into the liver (data not
shown). After three weeks liver metastases could be
detected by MRI. The T1 weighted 3D-Flash sequences
proved to be an excellent technique for a three dimen-
sional picture of all anatomical structures. This was
accomplished within a short overall scanning time.
Primovist
® as a liver specific contrast medium imaged
the liver hyper intense and liver metastases as negatively
contrast enhanced lesions within the liver (Figure 6 and
7). The longitudinal change in number and volume of
metastases could be analyzed with the help of MRI
A BC
Figure 6 Liver metastases. A: contrast enhanced images (contrast medium Primovist
®) 3 weeks after splenic injection: mean liver volume was
1065 mm
3; mean volume of metastases was 66.9 mm
3; mean number of metastases was 5.3 B: macroscopic findings - arrows pointing at
identical sites of MRI and macroscopic specimen C: histopathology, magnification 200 x; bar: 100 μm; arrows mark invasive margin at normal
liver tissue
A B
C D
Figure 7 Liver metastases. A: T2-weighted sequences of liver
metastasis B: contrast-enhanced image using Primovist
® C:
macroscopic findings D: histopathology, magnification 200 ×; bar:
100 μm
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Page 7 of 14specific software. After three weeks an average of 5.3
metastases (range 3 - 8) with a mean volume of 66.9
mm
3 (range 40.3 - 103.4 mm
3 +/-32.8 mm
3)w a s
detected. After five weeks these had significantly
(p < 0.03) increased to an average of 8 metastases
(range 5 - 12) with a mean volume of 173.8 mm
3 (range
123.6 - 235.3 mm
3 +/-56.7 mm
3) After measuring the
total volume of the liver the percentage of the liver
volume that was taken up by the metastases could be
determined (Figure 9).
Dynamic contrast enhanced MRI (DCE-MRI) for the
imaging of tumour blood flow
For these studies altogether n = 5 mice were analyzed.
The low molecular weight contrast medium Gadovist
®
as well as the high molecular weight contrast medium
Gadomer
® resulted in an equivalent accumulation
within the vascular system (Figure 10 and 11). As
expected, Gadovist
®, the low molecular weight contrast
medium, showed higher accumulation within the
tumour than Gadomer
®.
For a better analysis of the tumour blood flow defined
contrast-enhanced areas of the tumour, the muscles of
the thigh, and the aorta were scanned. In these regions
of interest (ROI) a quantitative comparison of the differ-
ent signal intensities was carried out. These tests
showed that an analysis of the tumour blood flow was
possible and reproducible using either contrast medium.
However, using the same concentrations of the contrast
medium the two substances showed different signal
intensities within the vascular system. Analysing the
signal intensities within the aorta (ROI/mean) Gado-
mer
® showed values up to Δ1600 whereas Gadovist
®
showed values only up to Δ650. Also, within muscle
C D
A B
Figure 8 Invasive tumour and lymphnode metastases. A: local tumour growth after 3 weeks, MRI findings B: macroscopic findings; arrows
pointing at identical areas of MRI C: histopathology shows tumour invasion of small intestine D: histopathology shows lymphnode metastasis
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detectable. The low molecular weight Gadovist
® had a
significantly increased accumulation within these tissues
compared to the vascular system and therefore higher
signal intensities whereas the high molecular
weight Gadomer
® showed a significantly decreased
accumulation implying lower signal intensities within
muscle and tumour tissue compared to the vascular
system.
For tumour blood flow analyses we found a concen-
tration of the contrast medium of 0.0025 mmol/ml to
be ideal. Using this concentration the analysis of the
enhancement of the contrast medium employing VIBE
sequences was optimal. At the same time the otherwise
increasing possibility of biochemical interferences using
higher concentrations of contrast media could be
avoided.
Discussion
In vitro and in vivo experiments are necessary to better
understand the development and nature of malignant
tumours. Furthermore, models that resemble the human
situation are critical for developing and testing new
therapeutic strategies. Here we used a 7 Tesla MRI for
monitoring tumour growth and metastasis formation
within liver and lymphnodes in a murine pancreatic
cancer model. In addition, the blood flow within
tumours could be analyzed. This model reliably mimics
the clinical situation of diagnosing and monitoring pan-
creatic cancer patients by employing MRI [20,21].
The here utilized 7.0 Tesla small animal MRI scanner
by Bruker (ClinScan, Bruker, Ettlingen, Germany) is part
of a multidisciplinary core facility at Greifswald Univer-
sity. The basic work flow and work charts are similar to
Liver 3 weeks
Metastasis 3 week
Liver 5 weeks
Metastasis 5 weeks
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Figure 9 Liver metastases. Liver volume and volume of liver
metastases after 3 and 5 weeks
pre-injection      injection            1 min.               5 min.              10 min.
time in 
minutes
blood
tumour
muscle
Figure 10 Tumour blood flow analyses. Gadovist
® - changes of signal intensities (ΔSi) over time
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Page 9 of 14the already installed human MRI system which is con-
trolled by Siemens software as is the small animal MRI.
One new feature of the system, the possibility of gener-
ating breathing rate triggered sequences, has proved
indispensable. The depth of anaesthesia controls nicely
the breathing rate, enabling the investigator to keep the
rate fairly stable. This is essential for breathing rate trig-
gered sequences. Employing this technique, volumes of
parenchymatous organs liket h el i v e ro rt h ev o l u m eo f
solid tumours could be measured accurately down to
differences in size as small as 0.1 mm. In the past,
tumour growth and metastasis formation had been stu-
died by direct measurement after sacrificing the animal.
The MRI technique enables the researcher to monitor
tumour development over time, if necessary several
times, in the same animal. This has significantly reduced
the number of required animals for longitudinal studies.
At the same time, each mouse can serve as its own con-
trol comparing images at different time points. Also, for
treatment experiments, tumours and their response to
treatment can be easily monitored over time. The pre-
sented murine model in combination with the 7 Tesla
MRI scanner is an excellent example of multidisciplinary
cooperation. In this case radiologists, surgeons and phy-
sicians have shared their expertise to implement new
and valuable tumour models to further improve the
research of pancreatic cancer.
Many in vivo models have combined human cells and
immunodeficient mice [8-11]. These models suffer from
several short comings since normal tumour development
and the role of the otherwise crucial immune system can-
not be evaluated due to the impaired immune system.
Also, human cells may behave differently once xenotrans-
planted into different species [9]. Therefore, syngeneic
orthotopic tumour models in immunocompetent animals
offer much more realistic conditions for studying malig-
nancies and the impact on the immune system [12-15].
Modern techniques for studying the immune response,
in particular methods to investigate cell trafficking, may
employ modern MRI techniques [22-25].
Other tumour models have been introduced working
simply with subcutaneously injected tumour cells
[13,26]. The growth of these can be easily monitored by
simple palpation or the use of a calliper. However, the
microenvironment at the implantation site of the host
organ can influence the natural history of tumour
growth and the efficacy of antineoplastic agents. The
microenvironment of an orthotopic model resembles
that of naturally occurring tumours, and so experimen-
tal results in this model would be expected to have
more relevance than results in a subcutaneous model
[27]. However, for these models in vivo imaging systems
are required.
The first reports on the use of MRI in small animals
were published some 30 years ago [28]. The technique of
MRI has steadily improved and has covered an increasing
spectrum of applications. Nowadays, MRI technique pro-
vides a powerful tool for clinical imaging. Even for
pre-injection          injection                  1 min.                   5 min.                   10 min.
time in 
minutes
blood
tumour
muscle
Figure 11 Tumour blood flow analyses. Gadomer
® - changes of signal intensities (ΔSi) over time
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Page 10 of 14research applications it is broadly available, either as spe-
cial small animal MR scanners or in combination with
clinical devices. It offers good imaging performances and
provides a tool for translational research [29].
The determination of sizes or volumes of implanted
tumours without imaging techniques has employed the
measurement using callipers or histology. In subcuta-
neous models calliper measurement is reasonable, since
the mouse can be monitored over time without sacrifi-
cing it. In orthotopic tumour models this is not possible.
Only after sacrificing the animal tumour sizes/volumes
can be determined. Using callipers only approximations
of the actual size or volumes of in situ tumours are possi-
ble. Tomayko et al. [19] have published extensively on
mathematical formulas to correctly measure e.g. ellipsoid
tumours. We have used the formula LxWxHxΠ/6 which
has a correlation coefficient of 0.98 to 0.99. Even in larger
or more irregularly shaped tumours the correlation is up
to 0.92. Only for tumours larger than 17.0 g the coeffi-
cient will be r = 0.79, which is still acceptable. However,
these formulas have been developed for subcutaneous
tumours. MR avoids the necessity of sacrificing animals
and irregular tumours can be measured more accurately.
Using histology we have found a very close correlation
between histological size and size determined by MR. In
fact, there was no difference in standard deviations.
However, due to shrinking during fixation, changes dur-
ing the processing of specimens including embedding,
cutting and staining histological measurements were
always somewhat smaller than MR measurements. The
correctness of MR measurements were validated by
algorithms developed by CIT and NIH specialists
employing MIPAV software [17]. Furthermore, we con-
firmed our results by measuring phantoms with defined
volumes with excellent recovery of the original volume.
The 7 Tesla small animal MRI scanner employed here
has an excellent spatial resolution. Tumours were always
readily detected. Using breathing controlled T2-
weighted sequences tumour volumes could be measured
very accurately. We could find a plane image resolution
of 0.17 mm × 0.13 mm when using slices of 0.7 mm.
Due to this high resolution MRI was highly suggestive
of tumour infiltration of surrounding organs if invasion
was present. When MRI was inconclusive histological
examination could differentiate tumour infiltration from
inflammation [30]. In fact, the same is true for the
human situation. Working with these models over time
including the combination of clinical, macroscopic,
microscopic and MR images had a significant training
effect and improved the accuracy of interpreting difficult
results or lesions of the images.
Several in vivo imaging systems other than MRI, such
as CT, CT-PET, ultrasound, bioluminescence and
fluorescence imaging techniques, have been developed
for determining tumour size and volume in orthotopic
experimental models [31]. These techniques have drama-
tically reduced the number of required animals according
to the 3R principles described by Russel and Burch 1959
[16]: each animal can be scanned repeatedly in a longitu-
dinal study, avoiding the need for large control groups.
However, the MRI technique combines several advan-
tages making it the preferred imaging technique. MRI
offers better discrimination of soft tissues and local reso-
lution [32]. Also, MRI offers a broader spectrum of dyna-
mically contrast enhanced scanning options and can, in
contrast to fluorescence techniques, image the complete
animal [33]. Also, the experimental set-up as well as
MRI-technique itself allows imaging using contrast
media, scanning the animal for longer periods and allow-
ing repeated imaging series. Finally, MRI does not
employ any radiation and, other than ultrasound, is less
investigator-dependent [34].
At the beginning of small animal MRI scanning many
problems had been caused by moving artefacts due to
difficulties in anaesthesia, the breathing of animals and
bowel motility. Modern techniques and the use of the 7
Tesla MRI scanner have greatly reduced these problems
[29]. The inhalative anaesthetic isoflurane and its appli-
cation via an adjustable evaporation system has shown
many advantages compared to intraperitoneal anaesthe-
sia using agents such as ketamine hydrochloride. The
amount of administered isoflurane is easily adjusted
allowing a reliable and stable control of breathing rates.
Despite its moderate cardiodepressive actions it is well
tolerated by animals for long imaging series of up to 60
minutes [35]. Furthermore, ketamine or xylazine may
have dramatic effects on the metabolism of small ani-
mals, in particular glucose metabolism, having a signifi-
cant impact on functional studies [36]. The reliable and
stable control of the breathing rate was required for
breathing rate triggered sequences. This led to reduced
artefacts and allowed exact measuring of tumour
volumes using T2-weighted sequences [37]. For similar
purposes the reduction of bowel motility by starving the
animals for 4 hours prior to MR imaging is a helpful
tool to reduce motion artefacts of the bowel. A further
reduction of bowel motility by N-butyl-scopolamine was
not required. Its short half-life of 5-10 minutes and its
possibly hazardous side effects might jeopardize MRI
analyses. Grimm et al. have published similar findings
concerning MR scanning of the pancreas [38]. All these
aforementioned supporting techniques improved the
focus, leading to a better visualization of the tumour
margins and detection of tumour invasion into sur-
rounding tissues. The injection of contrast media was
not necessary for these analyses.
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Page 11 of 14For MRI scans of the abdomen the whole body mouse
coil generated the best images. In contrast to conven-
tional surface coils it is a volume coil and has a very
high spatial resolution although a slightly reduced signal
to noise ratio. Conventional surface coils like the rat
brain coil (2 × 2), which could also be used, showed
decreased signal intensities with increased coil distance.
The whole body mouse coil avoided inhomogeneities of
the magnetic fields. This guarantees the continuous
good quality of images of the whole FoV including a
good signal to noise ratio.
For the induction of liver metastases several models
including the portal vein injection technique [39] and
the direct microinjection model [40] have been pub-
lished. We followed the suggestions of Ishizu et al. [41]
who established the splenic injection model. It is the
most efficient model and has the lowest rate of compli-
cations i.e. post surgical bleeding and local tumour
spread. So far, all animals have formed liver metastases
of the injected pancreatic cancer cell lines. With the
help of the liver specific contrast medium Primovist
®,
comparable to the human situation, metastatic lesions
could be accurately detected with a significantly
improved focus of the lesions. Using the MRI software
MIPAV this is an ideal model for comparative and ther-
apeutic studies involving either liver metastases alone or
liver metastases and their primary tumour. The amount
and size of liver lesions and, if present, the primary
tumour, can be exactly monitored over time without
sacrificing animals, again complying with the 3R princi-
ples [16].
I nt h i ss t u d yw eh a v er o u t i n e l yu s e dt h ei n t r a v e n o u s
contrast medium Primovist
® for the detection of liver
metastases and the intravenous contrast media Gado-
vist
® and Gadomer
® for tumour blood flow studies
employing an orthotopic murine pancreatic cancer
model. These models very closely resemble the human
situation. Interestingly, He et al. [42] described problems
with the intravenous use of contrast media whereas
Grimm et al. suggested the intraperitoneal application of
contrast media [38].
The low molecular weight contrast medium Gadovist
®
as well as the high molecular weight contrast medium
Gadomer
® can be used for dynamic contrast enhanced
imaging of the tumour blood flow and for analyzing dif-
ferent factors that might influence tumour blood flow.
Gadovist
® shows a much higher accumulation of con-
trast medium within the parenchyma of the tumour
than the high molecular weight Gadomer
®.H o w e v e r ,
high molecular weight contrast media could be used to
study tumour neoangiogenesis [35]. VEGF as the critical
cytokine in tumour neoangiogenesis could be therapeu-
tically blocked by inhibitors such as anti-VEGF-antibo-
dies or anti-VEGF-receptor-antibodies or other
therapeutic agents. Since VEGF could lead to an
increased permeability of tumour capillaries Gadomer
®
could show an increased accumulation in areas of
increased VEGF activity and a decreased accumulation
in areas of decreased or blocked activity. In those stu-
dies the dynamic contrast enhanced MRI would demon-
strate direct therapeutic effects. Also, they could be
monitored over time, again significantly reducing the
number of research animals as asked for by Russel and
Burch [16].
Conclusions
The analysis of murine pancreatic cancer models can be
done comparably to the human situation. Employing a 7
Tesla small animal MRI in a multidisciplinary environ-
ment involving radiologists, physicians and surgeons,
allows the exact clinical detection and monitoring of
tumour growth, tumour volumes, lymphnode and liver
metastasis formation as well as the tumour blood flow.
The number of research animals can be significantly
reduced in longitudinal studies according to the 3R
principles. The presented models can be used for ima-
g i n gs t u d i e sa sw e l la sn o n - s u r g i c a la n ds u r g i c a lt r e a t -
ment purposes.
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